Outlook Therapeutics plunges 60% as FDA denies Lytenava approval

Outlook Therapeutics shares tumbled more than 60% after the FDA again rejected its application to approve Lytenava for treating wet age-related macular degeneration. The agency said it cannot approve the drug in its current form, marking the second rejection in six months. The company said it disagrees with the decision but remains committed to seeking US approval.